0R15 8539.0 2.1534% 0R1E 8600.0 3.3654% 0M69 None None% 0R2V 190.25 -0.1312% 0QYR 1345.5 2.0871% 0QYP 424.0 0.5931% 0LCV 146.6464 -1.3147% 0RUK None None% 0RYA 1631.0 -0.6094% 0RIH 171.3 0.9131% 0RIH 174.9 2.1016% 0R1O 186.0 9820.0% 0R1O None None% 0QFP None None% 0M2Z 298.3 -0.6495% 0VSO None None% 0R1I None None% 0QZI 474.5 0.6363% 0QZ0 220.0 0.0% 0NZF None None%
Last update at 2024-05-16T15:35:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -83.41100M | -166.00400M | -73.15300M | -80.48400M | -62.02500M |
| Minority interest | - | - | - | - | - |
| Net income | -91.02500M | -167.61300M | -61.24400M | -72.21600M | -53.11900M |
| Selling general administrative | 157.45M | 161.75M | 71.39M | 66.06M | 41.09M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 123.81M | 73.19M | 46.88M | 25.62M | 16.02M |
| Reconciled depreciation | 31.87M | 24.69M | 17.34M | 14.85M | 6.36M |
| Ebit | -98.47900M | -164.53300M | -73.06000M | -80.89300M | -61.60200M |
| Ebitda | -60.90500M | -139.17800M | -55.63400M | -65.62500M | -55.24600M |
| Depreciation and amortization | 37.57M | 25.36M | 17.43M | 15.27M | 6.36M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -98.47900M | -164.53300M | -73.06000M | -80.89300M | -62.17600M |
| Other operating expenses | 297.08M | 298.19M | 186.92M | 132.95M | 94.70M |
| Interest expense | 1.63M | 0.91M | 0.75M | 0.61M | 0.42M |
| Tax provision | 7.61M | 1.61M | -11.90900M | -8.26800M | -8.90600M |
| Interest income | 5.94M | 0.22M | 0.09M | 0.52M | 0.57M |
| Net interest income | 4.31M | -0.68400M | -0.65600M | -0.09600M | 0.15M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 7.61M | 1.61M | -11.90900M | -8.26800M | -8.90600M |
| Total revenue | 198.60M | 133.66M | 113.86M | 52.06M | 32.52M |
| Total operating expenses | 222.29M | 237.73M | 119.94M | 106.51M | 78.19M |
| Cost of revenue | 74.79M | 60.47M | 66.98M | 26.44M | 16.51M |
| Total other income expense net | 15.07M | -1.47100M | -0.09300M | 0.41M | 0.15M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -91.02500M | -167.61300M | -61.24400M | -72.21600M | -53.11900M |
| Net income applicable to common shares | -91.02500M | -167.61300M | -61.24400M | -72.21600M | -53.11900M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 823.89M | 841.87M | 281.21M | 164.74M | 175.19M |
| Intangible assets | 30.04M | 23.00M | 22.87M | 16.52M | 6.41M |
| Earning assets | - | - | - | - | - |
| Other current assets | 2.06M | 69.07M | 86.66M | 71.39M | 30.39M |
| Total liab | 130.33M | 137.89M | 95.28M | 55.21M | 32.30M |
| Total stockholder equity | 693.56M | 703.98M | 185.93M | 109.53M | 142.89M |
| Deferred long term liab | 29.69M | 22.61M | 22.42M | 16.52M | 6.41M |
| Other current liab | 64.38M | 81.95M | 39.14M | 22.77M | 9.10M |
| Common stock | 0.08M | 0.08M | 0.04M | 0.03M | 0.03M |
| Capital stock | 0.08M | 0.08M | 0.04M | 0.03M | 0.03M |
| Retained earnings | -105.99100M | -15.90200M | -459.02300M | -397.77900M | -325.56300M |
| Other liab | 8.75M | 10.65M | 1.50M | 1.41M | 1.00M |
| Good will | - | - | - | - | - |
| Other assets | 7.68M | 28.68M | 23.86M | 16.87M | 6.41M |
| Cash | 356.78M | 487.84M | 80.86M | 13.09M | 35.32M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 102.53M | 105.05M | 72.18M | 36.73M | 21.79M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -322.68000M | -463.03600M | -57.23100M | 5.99M | -25.82100M |
| Short term debt | 15.05M | 2.61M | 2.04M | 2.02M | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 34.10M | 24.80M | 23.63M | 19.08M | 9.50M |
| Other stockholder equity | 799.46M | 719.80M | 644.92M | 507.27M | 468.42M |
| Property plant equipment | 63.20M | 61.92M | 53.20M | 43.35M | 26.46M |
| Total current assets | 638.00M | 750.61M | 203.15M | 104.51M | 142.32M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | 693.21M | 703.58M | 185.49M | 109.53M | 142.89M |
| Short term investments | 119.41M | 130.63M | - | - | 58.00M |
| Net receivables | 38.10M | 60.97M | 75.80M | 65.98M | 24.44M |
| Long term debt | 0.00000M | 9.50M | 9.50M | 9.50M | 9.50M |
| Inventory | 87.70M | 63.07M | 35.63M | 20.03M | 18.60M |
| Accounts payable | 23.10M | 20.49M | 31.01M | 11.95M | 10.53M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 119.41M | 130.63M | 0.55M | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 185.89M | 91.26M | 78.06M | 60.22M | 32.87M |
| Capital lease obligations | 34.10M | 15.30M | 14.13M | 9.58M | 0.00000M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -65.79400M | -131.37500M | -0.54800M | 58.00M | 58.00M |
| Change to liabilities | 4.43M | 33.57M | 33.66M | 12.80M | 6.47M |
| Total cashflows from investing activities | -65.79400M | -161.98500M | -26.93900M | 28.52M | -17.27200M |
| Net borrowings | -13.61100M | -2.36100M | -2.05800M | -1.70800M | -1.70800M |
| Total cash from financing activities | -13.71500M | 622.90M | 158.58M | -1.98800M | 98.40M |
| Change to operating activities | - | - | - | - | - |
| Net income | -83.41100M | -166.00400M | -73.15300M | -80.48400M | -53.11900M |
| Change in cash | -131.06200M | 406.98M | 67.77M | -22.22900M | -22.47600M |
| Begin period cash flow | 487.84M | 80.86M | 13.09M | 35.32M | 57.80M |
| End period cash flow | 356.78M | 487.84M | 80.86M | 13.09M | 35.32M |
| Total cash from operating activities | -49.38700M | -53.82600M | -63.80600M | -48.67900M | -55.50900M |
| Issuance of capital stock | 3.75M | 642.14M | 163.96M | 0.28M | 100.33M |
| Depreciation | 31.87M | 24.69M | 17.34M | 14.85M | 6.36M |
| Other cashflows from investing activities | 3.44M | 0.21M | 0.08M | 0.81M | 0.53M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -24.71700M | -27.44400M | -15.59200M | -1.43200M | -12.15400M |
| Change to account receivables | -7.40200M | 10.89M | -41.48400M | -3.52500M | -12.72600M |
| Sale purchase of stock | - | - | 163.96M | 0.28M | 100.33M |
| Other cashflows from financing activities | -7.96600M | -19.23900M | -5.37800M | -2.26400M | -1.92300M |
| Change to netincome | 37.45M | 72.08M | 3.52M | 0.85M | 9.09M |
| Capital expenditures | 42.23M | 30.82M | 26.47M | 30.29M | 17.80M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -27.68500M | 17.02M | -23.42100M | 7.84M | -18.40900M |
| Stock based compensation | 48.78M | 62.45M | 6.86M | 9.88M | 3.49M |
| Other non cash items | -18.94600M | 0.68M | 0.66M | 0.10M | 6.18M |
| Free cash flow | -91.62100M | -84.64300M | -90.27800M | -78.97000M | -73.31200M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ONT Oxford Nanopore Technologies Ltd |
-2.0 1.76% | 111.50 | - | - | 10.88 | 2.75 | 8.77 | -16.7946 |
| GNS Genus PLC |
-14.0 0.74% | 1880.00 | 42.59 | 25.71 | 2.08 | 2.46 | 2.31 | 16.39 |
| PRTC PureTech Health plc |
-0.5 0.22% | 222.00 | - | - | 35.55 | 1.04 | 95.87 | -4.5333 |
| AVCT Avacta Group PLC |
-0.75 1.69% | 43.50 | - | - | 23.19 | 14.78 | 20.75 | -10.4566 |
| BVXP Bioventix |
- -% | 4375.00 | 27.22 | 25.97 | 18.06 | 18.93 | 17.37 | 21.69 |
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a nanopore based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in the Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company operates in Life Science Research Tools and Covid Testing segments. It offers MinION, a portable device for DNA and RNA; GridION, a flexible and self-contained benchtop nanopore sequencer to run and analyse up to five MinION or Flongle flow cells; MinION Mk 1C, a nano pore-based sequencer with analysis software and connectivity for self-contained and portable sequencing; Flongle, an adapter for MinION or GridION that enables DNA sequencing or cDNA sequencing on smaller and single-use flow cells; and PromethION 2 Solo, a sequencer for two PromethION flow cells. The company also provides PromethION 2, a self-contained benchtop nanopore sequencer; PromethION 24, which provides single or multiple users with access to terabases of sequencing data; PromethION 48, a sequencing device with high-output flow cells; VolTRAX, an automated library prep for nanopore analyses; and Q-Line, a sequencing for applied applications, as well as products for SAR-Cov-2 testing. Its platform enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies plc in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is headquartered in Oxford, the United Kingdom.
Gosling Building, Oxford, United Kingdom, OX4 4DQ
| Name | Title | Year Born |
|---|---|---|
| Dr. Gordon S. Sanghera | Co-Founder, CEO & Director | NA |
| Prof. Hagan Bayley Ph.D. | Co-Founder & Member of Technical Advisory Board | NA |
| Mr. Tim Cowper | CFO & Director | NA |
| Mr. Rhodri Davies | VP of Operations | NA |
| Mr. Clive G. Brown | CTO & Director | NA |
| Mr. John Schoellerman | Sr. VP of Corp. Devel. & Investor Relations | NA |
| Mr. Jordan Herman | Sr. VP & Gen. Counsel | NA |
| Mr. Richard Compton | Sr. VP of Sales & Commercial Operations | NA |
| Ms. Sara Agee Le | VP of Global Marketing | NA |
| Ms. Sarah Lapworth | VP of Global HR | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
UK 
AU
CA
US
NZ
Please wait processing your request...